[ad_1]
The Wisconsin Division of Well being Companies has entered right into a contract with publicly-traded firm Pear Therapeutics to supply its reSET and reSET-O prescription digital therapeutics to Wisconsin residents with substance use dysfunction and opioid use dysfunction.
Pear’s reSET, a cell software used to assist deal with substance use dysfunction, acquired FDA De Novo clearance in 2017. The Boston-based firm’s reSET-O acquired 510(k) clearance in 2018.
Wisconsin’s DHS will make reSET and reSET-O out there by way of collaborating suppliers inside outpatient therapy settings, together with packages that provide prescriptions for buprenorphine, a medicine that can be utilized to deal with opioid dependence.
Pear tells MobiHealthNews, “[The deal] will present underserved populations in various demographics and areas throughout the state with entry to reSET and reSET-O.”
THE LARGER TREND
Pear wasn’t proof against the layoffs many digital well being firms noticed this previous summer time.
In July, Pear laid off roughly 25 of its workers, making up about 9% of its full-time workforce as a result of bigger financial atmosphere and the necessity to restructure operations to slim its short-term enterprise focus. In an SEC filing, Pear famous the discount will lower working bills by $28 million over 18 months, extending its money runway.
The layoff announcement got here three months after Pear launched a program to offer its reSET and reSET-O offerings via telehealth providers, with the primary being Pursue Care, which focuses on habit drugs.
[ad_2]
Source link
